Applied Molecular Transport : AMT Corporate Presentation March 2023

Corporate Overview

BREAKTHROUGH MEDICINES. THE NEXT AGE OF BIOLOGICS.

Forward-Looking Statements

This presentation and any accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well

as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "can be," "plan," "potential," "target," "will," "mission" or the negative of these terms or other similar expressions.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such statements include, but are not limited to, the potential of, and expectations regarding the potential of, potential benefits of, and expectations regarding AMT's technology platform, AMT-101 and AMT-126, statements regarding the market potential of AMT's product candidates, statements regarding AMT's Phase 2 clinical trials for AMT-101 and AMT's Phase 1 clinical trials for AMT-126, including the timing of such trials, enrollment of such trials, milestones and expectations relating to data readouts from such clinical trials, and AMT's ability to leverage its technology to expand its pipeline including our ability to expand our technology platform by developing therapies to treat respiratory diseases. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our technology platform to build a pipeline of product candidates; uncertainty of developing biologic therapeutics; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercializing of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the COVID-19 pandemic on our operations; and other risks. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the company's filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation concerns product candidates that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). Those product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

2

Company

Summary

AMT-101(ORAL IL-10FUSION): Exploring partnership to advance chronic pouchitis, received Orphan Drug Designation, no FDA- approved therapy in pouchitis; ongoing Phase 2 trial in RA

AMT-126 (ORAL IL-22 FUSION): Evaluating next steps for the

program; IL-22 is a validated target in UC with broad potential in additional diseases associated with GI epithelial barrier defects

NOVEL ORAL BIOLOGICS PLATFORM is proven engine for

pipeline development and partnering opportunities

3

Two Clinical Product Candidates: AMT-101 Advancing in Pouchitis and Evaluating Next Steps for AMT-126

PRODUCT

RESEARCH

PRECLINICAL

PHASE I

PHASE 2

PHASE 3

AMT-101

Oral IL-10

AMT-126

Oral IL-22

CHRONIC POUCHITIS - Orphan Drug Designation granted

RHEUMATOID ARTHRITIS

GI BARRIER REPAIR

Research

Oral and Respiratory

MULTIPLE TARGET, PLATFORM OPPORTUNITIES

AMT maintains worldwide rights to all product candidates and research programs.

4

AMT-101

Oral GI-SelectiveIL-10 Fusion

Immunology and Inflammation

5